BR112022003760A2 - Análogos de compstatina e seus usos médicos - Google Patents

Análogos de compstatina e seus usos médicos

Info

Publication number
BR112022003760A2
BR112022003760A2 BR112022003760A BR112022003760A BR112022003760A2 BR 112022003760 A2 BR112022003760 A2 BR 112022003760A2 BR 112022003760 A BR112022003760 A BR 112022003760A BR 112022003760 A BR112022003760 A BR 112022003760A BR 112022003760 A2 BR112022003760 A2 BR 112022003760A2
Authority
BR
Brazil
Prior art keywords
compstatin
analogs
introduction
medical uses
inhibiting activity
Prior art date
Application number
BR112022003760A
Other languages
English (en)
Portuguese (pt)
Inventor
Pernille Tofteng Shelton Anne
Fischer Munch Henrik
Original Assignee
Zp Spv 3 K/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zp Spv 3 K/S filed Critical Zp Spv 3 K/S
Publication of BR112022003760A2 publication Critical patent/BR112022003760A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
BR112022003760A 2019-08-27 2020-08-26 Análogos de compstatina e seus usos médicos BR112022003760A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19193925 2019-08-27
EP20172189 2020-04-29
PCT/EP2020/073905 WO2021037942A1 (en) 2019-08-27 2020-08-26 Compstatin analogues and their medical uses

Publications (1)

Publication Number Publication Date
BR112022003760A2 true BR112022003760A2 (pt) 2022-05-31

Family

ID=72178552

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003760A BR112022003760A2 (pt) 2019-08-27 2020-08-26 Análogos de compstatina e seus usos médicos

Country Status (14)

Country Link
US (1) US20220306695A1 (https=)
EP (2) EP4021921A1 (https=)
JP (1) JP7711044B2 (https=)
KR (1) KR20220066287A (https=)
CN (1) CN114630836A (https=)
AU (1) AU2020338688A1 (https=)
BR (1) BR112022003760A2 (https=)
CA (1) CA3148536A1 (https=)
CO (1) CO2022003556A2 (https=)
ES (1) ES3049784T3 (https=)
IL (1) IL290858A (https=)
MX (1) MX2022002433A (https=)
TW (1) TW202128731A (https=)
WO (1) WO2021037942A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2020128624A (ru) 2018-02-27 2022-03-28 Зп Спв 3 К/С Аналоги компстатина и их медицинское применение
IL299870A (en) * 2020-07-16 2023-03-01 Zp Spv 3 K/S Complement factor C3 inhibitors and their medical uses
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
WO2023048151A1 (ja) * 2021-09-22 2023-03-30 塩野義製薬株式会社 ウイルス増殖阻害活性を有する環状ペプチド
CN120359233A (zh) * 2022-11-24 2025-07-22 阿麦达斯制药美国有限责任公司 用于基于载体的疗法的坎普他汀类似物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319897B1 (en) 1996-03-13 2001-11-20 John D. Lambris Peptides which inhibit complement activation
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
AU723268B2 (en) 1996-09-09 2000-08-24 Zealand Pharma A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
WO1999013899A1 (en) 1997-09-17 1999-03-25 Trustees Of The University Of Pennsylvania Peptides and peptidomimetics for inhibiting complement activation
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
CZ20013018A3 (cs) 1999-03-17 2002-02-13 Novo Nordisk A/S Způsob pro acylování aminoskupiny peptidu nebo proteinu a sloučenina
PT1549333E (pt) 2002-09-20 2012-01-03 Univ Pennsylvania Análogos de compstatina com actividade melhorada
EP2662089A3 (en) 2005-10-08 2014-02-19 Potentia Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
CN102977191B (zh) 2005-11-28 2016-08-10 宾夕法尼亚州大学理事会 有效的c3补体抑制素类似物
WO2008153963A1 (en) 2007-06-08 2008-12-18 The Trustees Of The University Of Pennsylvania Structure of compstatin-c3 complex and use for rational drug design
EP2340028B1 (en) * 2008-09-30 2018-06-27 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
CA2813049A1 (en) 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
CA2847862C (en) 2011-09-07 2021-01-12 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved pharmacokinetic properties
US9512180B2 (en) 2012-12-19 2016-12-06 The Regents Of The University Of California Compstatin analogs
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US20180057538A1 (en) * 2016-08-26 2018-03-01 The Regents Of The University Of California Potent and highly soluble pegylated compstatin peptides
RU2020128624A (ru) * 2018-02-27 2022-03-28 Зп Спв 3 К/С Аналоги компстатина и их медицинское применение

Also Published As

Publication number Publication date
AU2020338688A1 (en) 2022-03-24
KR20220066287A (ko) 2022-05-24
CO2022003556A2 (es) 2022-05-20
CN114630836A (zh) 2022-06-14
IL290858A (en) 2022-04-01
WO2021037942A1 (en) 2021-03-04
JP2022545916A (ja) 2022-11-01
TW202128731A (zh) 2021-08-01
US20220306695A1 (en) 2022-09-29
EP4021921A1 (en) 2022-07-06
ES3049784T3 (en) 2025-12-18
EP4272751B1 (en) 2025-09-24
EP4272751A2 (en) 2023-11-08
EP4272751C0 (en) 2025-09-24
CA3148536A1 (en) 2021-03-04
JP7711044B2 (ja) 2025-07-22
MX2022002433A (es) 2022-05-19
EP4272751A3 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
BR112022003760A2 (pt) Análogos de compstatina e seus usos médicos
CO2020011027A2 (es) Análogos de compstatina y sus usos médicos
BR112021019076A2 (pt) Composição farmacêutica e formulação para injeção subcutânea compreendendo uma variante de hialuronidase ph20 humana
ES2509883T3 (es) Antagonistas de glucagón
BRPI0811320A2 (pt) Surfactantes reconstituídos com propriedades melhoradas
BR112018067895A2 (pt) fibroína modificada, ácido nucléico, vetor de expressão, hospedeiro, e, produto.
CO2023001411A2 (es) Inhibidores del factor c3 del complemento y sus usos médicos
CY1123997T1 (el) Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου
CY1125528T1 (el) Νεα glp-1 αναλογα
BRPI1010120A2 (pt) composição de surfactante reconstituído melhorada contendo análogos de proteína b do surfactante (sp-b) e proteína c do surfactante ( sp-c)
MX9205985A (es) Epitopes de las celulas t de los alergenos principales del genero dermatophagoides y composiciones farmaceuticas que los contienen.
NO20081654L (no) Stabiliserte GLP-1-analoger
EA200900373A1 (ru) Реконструированные сурфактанты, обладающие улучшенными свойствами
BR112018073681A2 (pt) análogo recombinante isolado de uma alça de fusão da proteína e de flavivírus, análogo recombinante isolado de uma proteína e de flavivírus, sequência de dna ou rna recombinante isolada, sequência de dna recombinante isolada, célula hospedeira, célula hospedeira eucariótica, método de produção de um análogo, composição, composição (vacina) imunogênica capaz de induzir uma resposta imunológica num sujeito inoculado com a referida composição, molécula de ligação, análogo, composição ou molécula de ligação, método para a proteção de um sujeito contra a infecção por um flavivírus, kit de diagnóstico, e kit teste de diagnóstico
BR112022025123A2 (pt) Polipeptídeos mybpc3 e usos dos mesmos
PE20210185A1 (es) Apirasas solubilizadas, metodos y usos
WO2019195712A3 (en) Compstatin analogs with increased solubility and improved pharmacokinetic properties
BR112018072968A2 (pt) peptídeos monolipidados resistentes às proteases
BR112019003950A2 (pt) identificação de mutações em variantes de canalopsina que têm sensibilidade à luz melhorada e métodos de uso da mesma
WO2015110809A3 (en) Drug delivery system
BR112022005782A2 (pt) Proteína galectina 9 estabilizada recombinante, vetor recombinante, transformante, composição farmacêutica para prevenção ou tratamento de uma doença óssea, alimento funcional de saúde para prevenção ou melhora de uma doença óssea, e, uso de uma proteína galectina 9 estabilizada recombinante
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.
MX2022003598A (es) Composicion farmaceutica, que comprende la proteina galectina 9 recombinante estabilizada, para la prevencion o el tratamiento de la artritis reumatoide y enfermedades oseas.
WO2021160234A3 (en) Antimicrobial peptides from medicinal leeches
BR112023005798A2 (pt) Peptídeos amidados e seus equivalentes desamidados exibidos por hla-a*02 para uso em imunoterapia contra diferentes tipos de câncer